FindTrial
Sign In

Lusutrombopag

DRUG5 trials

Sponsors

Shionogi, Peking Union Medical College Hospital, The General Hospital of Western Theater Command

Conditions

Aplastic AnemiaChronic Liver DiseaseHematologic DisordersImmune ThrombocytopeniaImmune Thrombocytopenia (ITP)Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell TransplantationThrombocytopenia

Phase 2

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
TerminatedNCT01054443
ShionogiImmune Thrombocytopenia (ITP)
Start: 2010-03-18End: 2010-11-24Updated: 2021-03-18
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
TerminatedNCT01129024
ShionogiImmune Thrombocytopenia
Start: 2010-04-29End: 2011-06-30Updated: 2021-02-26

Phase 3

Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
CompletedNCT02389621
ShionogiChronic Liver Disease, Thrombocytopenia
Start: 2015-06-15End: 2017-04-19Updated: 2018-10-30

Phase 4

A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag
Not yet recruitingNCT06426043
Peking Union Medical College HospitalAplastic Anemia
Start: 2024-06-30End: 2025-08-31Target: 40Updated: 2024-05-23

Unknown Phase

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
RecruitingNCT07483385
The General Hospital of Western Theater CommandHematologic Disorders, Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
Start: 2026-01-13End: 2028-01-28Target: 45Updated: 2026-03-25

Related Papers

Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance
Advances in Therapy2022-07-292 citations
Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
2020-03-209 citations
947 Lusutrombopag for Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Who Are Undergoing Planned Invasive Procedures: Pooled Safety Analysis of Bleeding-Related Adverse Events
The American Journal of Gastroenterology2019-10-01
1016 Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Invasive Procedure: Pooled Safety Analysis From 3 Studies
The American Journal of Gastroenterology2019-10-01
PF697 LUSUTROMBOPAG IS A SAFE AND EFFICACIOUS TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF TWO PHASE 3 TRIALS
HemaSphere2019-06-012 citations
PF699 LUSUTROMBOPAG IS A SAFE TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING A SCHEDULED INVASIVE PROCEDURE: POOLED SAFETY ANALYSIS FROM 3 STUDIES
HemaSphere2019-06-011 citations
PF702 USE OF THE THROMBOPOIETIN RECEPTOR AGONIST LUSUTROMBOPAG FOR THROMBOCYTOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF 2 TRIALS
HemaSphere2019-06-01
PF341 LUSUTROMBOPAG FOR TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE UNDERGOING PLANNED INVASIVE PROCEDURES: POOLED SAFETY ANALYSIS OF BLEEDING‐RELATED ADVERSE EVENTS
HemaSphere2019-06-01
PF698 LUSUTROMBOPAG RELIABLY INCREASES PLATELETS REGARDLESS OF BASELINE PLATELET COUNTS IN THROMBOCYTOPENIC CHRONIC LIVER DISEASE PATIENTS UNDERGOING PLANNED INVASIVE PROCEDURES: RESULTS OF 2 PHASE 3 TRIALS
HemaSphere2019-06-01